-
EMA validates Soleno’s application for Prader-Willi syndrome treatment
Published: 1 day ago | (Link to MSN)
The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) submitted by Soleno Therapeutics for diazoxide choline…
-
EMA Validates Soleno Therapeutics’ Application for Diazoxide Choline Tablets to Treat Prader-Willi Syndrome
Published: 2 days ago | (Link to GeneOnline)
The European Medicines Agency (EMA) has officially vali […]
-
Katie Price shares loving tribute to her eldest son Harvey on his 23rd birthday
Published: 2 days ago | (Link to Daily Mail)
The former glamour model, 47, took to Instagram on his birthday eve to post a series of throwback snaps with Harvey as she celebrated his special day with…
-
Acadia Pharmaceuticals hires new SVP for Rare Disease unit By Investing.com
Published: 2 days ago | (Link to Investing.com Nigeria)
SAN DIEGO – Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a $3.71 billion market cap pharmaceutical company with excellent financial health according to…
-
DCCR now under review in EU as hyperphagia treatment in PWS
Published: 2 hours ago | (Link to Prader-Willi Syndrome News)
DCCR, approved in the U.S. as Vykat XR for treating hyperphagia in Prader-Willi syndrome patients, is now under review in the European Union.
-
EMA validates Soleno’s application for Prader-Willi syndrome treatment
Published: 3 days ago | (Link to Pharmaceutical Technology)
The EMA has validated the MAA submitted by Soleno Therapeutics for diazoxide choline prolonged-release tablets for Prader-Willi syndrome.
-
Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation
Published: 6 days ago | (Link to marketscreener.com)
Soleno Therapeutics said late Thursday that the European Medicines Agency validated the company’s marketing authorization application for diazoxide choline…
-
Soleno seeks EU approval for Prader-Willi syndrome treatment
Published: 6 days ago | (Link to Investing.com Australia)
REDWOOD CITY, Calif. – Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company valued at $3.73 billion, announced today that its Marketing…
-
Soleno Therapeutics’ (SLNO) MAA for PWS Treatment Validated by EMA | SLNO Stock News
Published: 6 days ago | (Link to GuruFocus)
Soleno Therapeutics (SLNO) recently announced that their Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets has been…
-
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
Published: 6 days ago | (Link to Insider Monkey)
Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) validated its Marketing…
Posted inPrader Willi Syndrome News